Abbott Pakistan has managed to stay in good shape during 2015. Despite the issues faced by the pharmaceutical industry that is hurting the growth of the industry, Abbott's profitability keeps on getting bigger and better. The bottom line during the year flaunted a significant rise of 27 percent year-on-year. Mind you, this much larger number than what company has achieved during 2009-2013.
The company has seen 8 percent year-on-year growth in its top line. Taking a clue from the nine month period in September 2015, pharmaceutical segment contributed 73 percent to the sales revenue of the company, followed by nutrition business (17 percent) and others (10 percent). Although pharmaceutical sector continues to dominate the portfolio, its dependence is relatively lower in Abbott's product portfolio when compared to the industry average.
The growth in the top line is likely to have come from the volumetric rise in the pharmaceutical segment and strong revenue generation from the consumer healthcare business. Others segment which includes general health care, diagnostic and diabetes care has been under pressure for some time owing to regression in Mospel sales. But, things are improving.
The gross profit margins improved during the period due to the favourable product mix and core cost control. The company has also witnessed higher export sales and Afghanistan was the top destination of Abbott's products. Abbott's has seen its selling, and distribution expense come down due to decline in the fuel prices.
Moreover, the result was accompanied with a final dividend of Rs20 per share, which is in addition to interim dividend of Rs10 already disbursed by the company.
Comments
Comments are closed.